JAK1 and hemophagocytic syndrome: By the modulation of IFN-γ and other cytokines, the JAK1/2 inhibitor ruxolitinib reduced immune cell proliferation and activation, and reversed organ pro-inflammatory damage on experimental models of HLH [59,60].